Abd Tahrani is currently the International Medical Vice President, Obesity & NASH, Clinical Drug Development, Novo Nordisk in Copenhagen. He is also an honorary Senior Lecturer in Metabolic Endocrinology and Obesity Medicine at the University of Birmingham (UoB) and an Honorary Consultant in Endocrinology, Diabetes & Weight Management at the University Hospitals Birmingham NHS Foundation Trust.
Prior to joining Novo Nordisk, he was the lead for translational research in the Centre of Endocrinology, Diabetes and Metabolism (CEDAM), Birmingham Health Partners and the chair of the clinical committee of the Association for the Study of Obesity (ASO) UK. Abd is currently an associate editor for the European Journal of Endocrinology and the chair of the Type 2 Diabetes Research Steering Group in Diabetes UK and a member of the nutrition and obesity group of the ESE.
Abd received several awards including NIHR research training fellowship (2008), NIHR Clinician Scientist (2012), the American Academy of Sleep Medicine Young investigator award in OSA research (2013), and SCOPE National & International Fellowships from the World Obesity Federation in (2014 & 2020). Abd’s research themes included: 1) the metabolic consequences of sleep-related disorders, 2) obesity management & health care delivery, 3) diabetes-related neuropathy.
Abd has published over 170 peer reviewed articles and delivered more than 110 invited talks in the leading conferences globally. Abd held a number of positions before joining Novo Nordisk including being a trustee of ASO (UK), a panel member of the British Sleep Society Research Committee, an Expert advisor to NICE technology appraisals in obesity and neuropathy, a member of the Obesity Policy Engagement Network (OPEN) UK and a member of the strategic council of the Obesity All Party Parliamentary Group (Obesity APPG). He is a regular peer reviewer to the leading journals and research funding organisations. Till recently he was a senior editor for BMC Endocrine Disorders.